

Date: March 03, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Intimation for giving corporate guarantee for additional credit facilities availed by Havix Group Inc. D/B/A Aavis Pharmaceuticals a material subsidiary of the Company from HDFC Bank Limited

Ref.: Our intimation dated July 10, 2025

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in furtherance of our earlier intimation dated July 10, 2025, we would like to inform you that the Company has issued Corporate Guarantee for the additional credit facilities availed by Havix Group Inc. D/B/A Aavis Pharmaceuticals, USA - Material Subsidiary of the Company, from HDFC Bank Limited for an amount upto USD 1,500,000/- (US Dollars One Million Five Hundred Thousand Only).

Details as required to be furnished under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith as **Annexure I**.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure I

Details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1.	Name of party for which such guarantee or indemnity or surety was given	Havix Group Inc. D/B/A Aavis Pharmaceuticals, USA - Material Subsidiary of the Company ("Havix")
2.	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The promoter and promoter group have interest to the extent of their directorship in Havix-Material Subsidiary of the Company. The corporate guarantee extended is at arm's length.
3.	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	The Corporate Guarantee of upto USD 1,500,000/- (US Dollars One Million Five Hundred Thousand Only) is given by the Company on March 03, 2026, in favor of HDFC Bank Ltd. ("Bank") to secure the additional credit facilities availed by Havix from the Bank. The Corporate Guarantee is valid till the closure of the credit facilities or the tenure of the credit facilities whichever is earlier. The maximum tenure of credit facilities is 10 (ten) years.
4.	Impact of such guarantee or indemnity or surety on listed entity	At this point, there is no impact of this guarantee on the Company other than disclosure in the financial statements as a Contingent Liability.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263